GCGR and fibrosis: Mazdutide (IBI362 or LY3305677), a long-acting synthetic peptide analog of oxyntomodulin acting as a dual agonist of the GLP-1 and glucagon receptors, has shown promising results in managing obesity, diabetes, and conditions related to hepatic fibrosis and steatosis.